Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 17.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 495,976 shares of the company’s stock after buying an additional 72,232 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.97% of Mirum Pharmaceuticals worth $36,360,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. CWM LLC raised its position in Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares in the last quarter. Legal & General Group Plc lifted its holdings in Mirum Pharmaceuticals by 0.4% in the second quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after acquiring an additional 176 shares during the period. MCF Advisors LLC boosted its position in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after purchasing an additional 185 shares in the last quarter. Jones Financial Companies Lllp boosted its position in Mirum Pharmaceuticals by 34.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Mirum Pharmaceuticals by 2.6% during the 3rd quarter. Arizona State Retirement System now owns 10,984 shares of the company’s stock worth $805,000 after purchasing an additional 275 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Leerink Partners cut their target price on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Citizens Jmp decreased their price objective on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating for the company in a research report on Thursday, February 26th. Finally, Royal Bank Of Canada lowered their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Insiders Place Their Bets

In related news, CFO Eric Bjerkholt sold 1,053 shares of the firm’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $101,288.07. Following the transaction, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. This trade represents a 2.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $99,994.40. Following the completion of the sale, the senior vice president owned 4,503 shares in the company, valued at approximately $465,159.90. The trade was a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 45,136 shares of company stock valued at $4,352,029. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Trading Down 2.1%

Shares of NASDAQ:MIRM opened at $89.78 on Friday. The business’s 50 day moving average price is $95.13 and its 200-day moving average price is $80.50. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $109.28. The firm has a market capitalization of $5.42 billion, a price-to-earnings ratio of -187.04 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.Mirum Pharmaceuticals’s revenue was up 49.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.00 EPS. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.